NAS:RDHL (Israel)  
Redhill Biopharma Ltd logo

Redhill Biopharma Ltd

$ 0.50 -0.0036 (-0.72%) 11:15 AM EST
P/E:
N/A
P/B:
0
Market Cap:
$ 31.90M
Enterprise V:
$ 98.20M
Volume:
1.14M
Avg Vol (2M):
1.49M
Also Trade In:
Volume:
1.14M
Market Cap $:
31.90M
PE Ratio:
N/A
Avg Vol (2-Month):
1.49M
Enterprise Value $:
98.20M
PB Ratio:
0
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 0.3
Equity-to-Asset -0.03
Debt-to-Equity -18.12
Debt-to-EBITDA -1.63
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.35
Distress
Grey
Safe
Beneish M-Score -3.45
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 24.78
9-Day RSI 22.25
14-Day RSI 25.86
6-1 Month Momentum % -64.31
12-1 Month Momentum % -80.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.98
Quick Ratio 0.79
Cash Ratio 0.39
Days Inventory 93.18
Days Sales Outstanding 123.44
Days Payable 81.15

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.7

Financials (Next Earnings Date:2022-11-30 Est.)

RDHL's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RDHL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 83.418
EPS (TTM) ($) -1.9
Beta 1.79
Volatility % 77.13
14-Day RSI 25.86
14-Day ATR ($) 0.062512
20-Day SMA ($) 0.698505
12-1 Month Momentum % -80.36
52-Week Range ($) 0.4726 - 6.5
Shares Outstanding (Mil) 63.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Redhill Biopharma Ltd Filings

Document Form Filing Date
No Filing Data

Redhill Biopharma Ltd Analysis

Share your research

Headlines

See More
No news.